Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.

Supriya Krishnan, Jeffrey T. Schouten, Benjamin Atkinson, Todd T Brown, David Wohl, Grace A. McComsey, Marshall J. Glesby, Cecilia Shikuma, Richard Haubrich, Pablo Tebas, Thomas B. Campbell, Denise L. Jacobson

Research output: Contribution to journalArticle

Abstract

Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease and diabetes, many of which are associated with HIV and antiretroviral therapy (ART). We examined prevalence and incidence of MetS and risk factors for MetS in ART-naive HIV-infected individuals starting ART. MetS, defined by the Adult Treatment Panel III criteria, was assessed at and after ART initiation in HIV-infected individuals who enrolled in selected AIDS Clinical Trials Group trials and were followed long-term after these trials as part of the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. Cox proportional hazards models were used to examine risk factors of incident MetS. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CI) are reported. At ART initiation, the prevalence of MetS was 20%. After ART initiation, the incidence of MetS was 8.5 per 100 person-years. After adjusting for demographics and body mass index, the risk of MetS was decreased for CD4+ T-cell counts >50 cells per cubic millimeter (aHR = 0.62, 95% CI = 0.43 to 0.90 for CD4 >500), and the risk was increased for HIV-1 RNA >400 copies per milliliter (aHR = 1.55 (95% CI = 1.25 to 1.92) and use of a protease-inhibitor (PI)-based regimen [relative to no PI use, aHR = 1.25 (95% CI = 1.04 to 1.51) for any PI use]. In HIV-infected individuals on ART, virologic suppression and maintenance of high CD4+ T-cell counts may be potentially modifiable factors that can reduce the risk of MetS. The effect of MetS on the risk of cardiovascular disease and diabetes needs to be evaluated.

Original languageEnglish (US)
Pages (from-to)381-389
Number of pages9
JournalJournal of acquired immune deficiency syndromes (1999)
Volume61
Issue number3
StatePublished - 2012
Externally publishedYes

Fingerprint

HIV
Protease Inhibitors
Confidence Intervals
Therapeutics
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
Cardiovascular Diseases
Clinical Trials
T-Lymphocytes
Incidence
Proportional Hazards Models
HIV-1
Body Mass Index
Demography
RNA

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. / Krishnan, Supriya; Schouten, Jeffrey T.; Atkinson, Benjamin; Brown, Todd T; Wohl, David; McComsey, Grace A.; Glesby, Marshall J.; Shikuma, Cecilia; Haubrich, Richard; Tebas, Pablo; Campbell, Thomas B.; Jacobson, Denise L.

In: Journal of acquired immune deficiency syndromes (1999), Vol. 61, No. 3, 2012, p. 381-389.

Research output: Contribution to journalArticle

Krishnan, S, Schouten, JT, Atkinson, B, Brown, TT, Wohl, D, McComsey, GA, Glesby, MJ, Shikuma, C, Haubrich, R, Tebas, P, Campbell, TB & Jacobson, DL 2012, 'Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.', Journal of acquired immune deficiency syndromes (1999), vol. 61, no. 3, pp. 381-389.
Krishnan, Supriya ; Schouten, Jeffrey T. ; Atkinson, Benjamin ; Brown, Todd T ; Wohl, David ; McComsey, Grace A. ; Glesby, Marshall J. ; Shikuma, Cecilia ; Haubrich, Richard ; Tebas, Pablo ; Campbell, Thomas B. ; Jacobson, Denise L. / Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. In: Journal of acquired immune deficiency syndromes (1999). 2012 ; Vol. 61, No. 3. pp. 381-389.
@article{dccfc8bd466645ae9e34e550cbbd6c75,
title = "Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.",
abstract = "Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease and diabetes, many of which are associated with HIV and antiretroviral therapy (ART). We examined prevalence and incidence of MetS and risk factors for MetS in ART-naive HIV-infected individuals starting ART. MetS, defined by the Adult Treatment Panel III criteria, was assessed at and after ART initiation in HIV-infected individuals who enrolled in selected AIDS Clinical Trials Group trials and were followed long-term after these trials as part of the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. Cox proportional hazards models were used to examine risk factors of incident MetS. Adjusted hazard ratios (aHRs) and 95{\%} confidence intervals (CI) are reported. At ART initiation, the prevalence of MetS was 20{\%}. After ART initiation, the incidence of MetS was 8.5 per 100 person-years. After adjusting for demographics and body mass index, the risk of MetS was decreased for CD4+ T-cell counts >50 cells per cubic millimeter (aHR = 0.62, 95{\%} CI = 0.43 to 0.90 for CD4 >500), and the risk was increased for HIV-1 RNA >400 copies per milliliter (aHR = 1.55 (95{\%} CI = 1.25 to 1.92) and use of a protease-inhibitor (PI)-based regimen [relative to no PI use, aHR = 1.25 (95{\%} CI = 1.04 to 1.51) for any PI use]. In HIV-infected individuals on ART, virologic suppression and maintenance of high CD4+ T-cell counts may be potentially modifiable factors that can reduce the risk of MetS. The effect of MetS on the risk of cardiovascular disease and diabetes needs to be evaluated.",
author = "Supriya Krishnan and Schouten, {Jeffrey T.} and Benjamin Atkinson and Brown, {Todd T} and David Wohl and McComsey, {Grace A.} and Glesby, {Marshall J.} and Cecilia Shikuma and Richard Haubrich and Pablo Tebas and Campbell, {Thomas B.} and Jacobson, {Denise L.}",
year = "2012",
language = "English (US)",
volume = "61",
pages = "381--389",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals.

AU - Krishnan, Supriya

AU - Schouten, Jeffrey T.

AU - Atkinson, Benjamin

AU - Brown, Todd T

AU - Wohl, David

AU - McComsey, Grace A.

AU - Glesby, Marshall J.

AU - Shikuma, Cecilia

AU - Haubrich, Richard

AU - Tebas, Pablo

AU - Campbell, Thomas B.

AU - Jacobson, Denise L.

PY - 2012

Y1 - 2012

N2 - Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease and diabetes, many of which are associated with HIV and antiretroviral therapy (ART). We examined prevalence and incidence of MetS and risk factors for MetS in ART-naive HIV-infected individuals starting ART. MetS, defined by the Adult Treatment Panel III criteria, was assessed at and after ART initiation in HIV-infected individuals who enrolled in selected AIDS Clinical Trials Group trials and were followed long-term after these trials as part of the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. Cox proportional hazards models were used to examine risk factors of incident MetS. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CI) are reported. At ART initiation, the prevalence of MetS was 20%. After ART initiation, the incidence of MetS was 8.5 per 100 person-years. After adjusting for demographics and body mass index, the risk of MetS was decreased for CD4+ T-cell counts >50 cells per cubic millimeter (aHR = 0.62, 95% CI = 0.43 to 0.90 for CD4 >500), and the risk was increased for HIV-1 RNA >400 copies per milliliter (aHR = 1.55 (95% CI = 1.25 to 1.92) and use of a protease-inhibitor (PI)-based regimen [relative to no PI use, aHR = 1.25 (95% CI = 1.04 to 1.51) for any PI use]. In HIV-infected individuals on ART, virologic suppression and maintenance of high CD4+ T-cell counts may be potentially modifiable factors that can reduce the risk of MetS. The effect of MetS on the risk of cardiovascular disease and diabetes needs to be evaluated.

AB - Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease and diabetes, many of which are associated with HIV and antiretroviral therapy (ART). We examined prevalence and incidence of MetS and risk factors for MetS in ART-naive HIV-infected individuals starting ART. MetS, defined by the Adult Treatment Panel III criteria, was assessed at and after ART initiation in HIV-infected individuals who enrolled in selected AIDS Clinical Trials Group trials and were followed long-term after these trials as part of the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. Cox proportional hazards models were used to examine risk factors of incident MetS. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CI) are reported. At ART initiation, the prevalence of MetS was 20%. After ART initiation, the incidence of MetS was 8.5 per 100 person-years. After adjusting for demographics and body mass index, the risk of MetS was decreased for CD4+ T-cell counts >50 cells per cubic millimeter (aHR = 0.62, 95% CI = 0.43 to 0.90 for CD4 >500), and the risk was increased for HIV-1 RNA >400 copies per milliliter (aHR = 1.55 (95% CI = 1.25 to 1.92) and use of a protease-inhibitor (PI)-based regimen [relative to no PI use, aHR = 1.25 (95% CI = 1.04 to 1.51) for any PI use]. In HIV-infected individuals on ART, virologic suppression and maintenance of high CD4+ T-cell counts may be potentially modifiable factors that can reduce the risk of MetS. The effect of MetS on the risk of cardiovascular disease and diabetes needs to be evaluated.

UR - http://www.scopus.com/inward/record.url?scp=85027917510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027917510&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 381

EP - 389

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -